CytomX Therapeutics (CTMX) Reports In-Line Q2 EPS

CytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of ($0.37), in-line with the analyst estimate of ($0.37). Revenue for the quarter came in at $18.17 million versus the consensus estimate of $18.11 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Reading (RDI) Tops Q2 EPS by 4c